322 related articles for article (PubMed ID: 29545344)
21. Humanized three-dimensional scaffold xenotransplantation models for myelodysplastic syndromes.
Altrock E; Sens-Albert C; Jann JC; Flach J; Riabov V; Schmitt N; Xu Q; Mehralivand A; Hecht A; Steiner L; Streuer A; Nowak V; Obländer J; Weimer N; Palme I; Jawhar A; Weis CA; Weyer V; Nolte F; Jawhar M; Metzgeroth G; Marx A; Groden C; Hofmann WK; Nowak D
Exp Hematol; 2022 Mar; 107():38-50. PubMed ID: 34952140
[TBL] [Abstract][Full Text] [Related]
22. Human cord blood (hCB)-CD34+ humanized mice fail to reject human acute myeloid leukemia cells.
Tanaskovic O; Verga Falzacappa MV; Pelicci PG
PLoS One; 2019; 14(9):e0217345. PubMed ID: 31536492
[TBL] [Abstract][Full Text] [Related]
23. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.
Woiterski J; Ebinger M; Witte KE; Goecke B; Heininger V; Philippek M; Bonin M; Schrauder A; Röttgers S; Herr W; Lang P; Handgretinger R; Hartwig UF; André MC
Int J Cancer; 2013 Oct; 133(7):1547-56. PubMed ID: 23526331
[TBL] [Abstract][Full Text] [Related]
24. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
26. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.
Griessinger E; Andreeff M
Haematologica; 2018 Jun; 103(6):921-923. PubMed ID: 29866886
[No Abstract] [Full Text] [Related]
27. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
28. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
29. Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
Horiguchi H; Kobune M; Kikuchi S; Yoshida M; Murata M; Murase K; Iyama S; Takada K; Sato T; Ono K; Hashimoto A; Tatekoshi A; Kamihara Y; Kawano Y; Miyanishi K; Sawada N; Kato J
Haematologica; 2016 Apr; 101(4):437-47. PubMed ID: 26802051
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
[TBL] [Abstract][Full Text] [Related]
31. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.
Carretta M; de Boer B; Jaques J; Antonelli A; Horton SJ; Yuan H; de Bruijn JD; Groen RWJ; Vellenga E; Schuringa JJ
Exp Hematol; 2017 Jul; 51():36-46. PubMed ID: 28456746
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
33. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
34. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
36. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice.
Bonnet D; Bhatia M; Wang JC; Kapp U; Dick JE
Bone Marrow Transplant; 1999 Feb; 23(3):203-9. PubMed ID: 10084250
[TBL] [Abstract][Full Text] [Related]
37. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
38. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
39. Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.
Gopalakrishnapillai A; Kolb EA; Dhanan P; Bojja AS; Mason RW; Corao D; Barwe SP
Front Oncol; 2016; 6():162. PubMed ID: 27446808
[TBL] [Abstract][Full Text] [Related]
40. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
